Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: Five year review Journal Article

Authors: Abramson, D. H.; Marr, B. P.; Brodie, S. E.; Dunkel, I.; Palioura, S.; Gobin, Y. P.
Article Title: Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: Five year review
Abstract: Background: Ophthalmic artery chemosurgery (OAC) for retinoblastoma was introduced by us 5 years ago for advanced intraocular retinoblastoma. Because the success was higher than with existing alternatives and systemic side effects limited we have now treated less advanced intraocular retinoblastoma (Reese-Ellsworth (RE) I-III and International Classification Retinoblastoma (ICRB) B and C). Methodology/Principal Findings: Retrospective review of 5 year experience in eyes with Reese Ellsworth (table 1) I (7 eyes), II (6 eyes) or III (6 eyes) and/or International Classification (table 2) B (19 eyes) and C (11 eyes) treated with OAC (melphalan with or without topotecan) introduced directly into the ophthalmic artery. Patient survival was 100%. Ocular event-free survival was 100% for Reese-Ellsworth Groups I, II and III (and 96% for ICRB B and C) at a median of 16 months follow-up. One ICRB Group C (Reese-Ellsworth Vb) eye could not be treated on the second attempt for technical reasons and was therefore enucleated. No patient required a port and only one patient required transfusion of blood products. The electroretinogram (ERG) was unchanged or improved in 14/19 eyes. Conclusions/Significance: Ophthalmic artery chemosurgery for retinoblastoma that was Reese-Ellsworth I, II and III (or International Classification B or C) was associated with high success (100% of treatable eyes were retained) and limited toxicity with results that equal or exceed conventional therapy with less toxicity. © 2012 Abramson et al.
Keywords: adolescent; adult; cancer survival; child; clinical article; event free survival; preschool child; child, preschool; disease-free survival; retrospective studies; young adult; advanced cancer; antineoplastic agents; disease free survival; topotecan; follow up; methodology; follow-up studies; antineoplastic agent; melphalan; retinoblastoma; drug effect; pathology; retina tumor; retinal neoplasms; retrospective study; infant; blood transfusion; enucleation; ophthalmic artery; chemosurgery; tumor classification; eye; eye surgery; electroretinogram; ophthalmic artery chemosurgery; ophthalmologic surgical procedures
Journal Title: PLoS ONE
Volume: 7
Issue: 4
ISSN: 1932-6203
Publisher: Public Library of Science  
Date Published: 2012-01-01
Start Page: e34120
Language: English
DOI: 10.1371/journal.pone.0034120
PROVIDER: scopus
PMCID: PMC3335846
PUBMED: 22545080
Notes: --- - "Export Date: 4 June 2012" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Brian Marr
    108 Marr
  2. Ira J Dunkel
    250 Dunkel
  3. David H Abramson
    247 Abramson
  4. Scott Brodie
    37 Brodie